FEDERAL COURT OF AUSTRALIA
Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCA 285
File number: NSD 2149 of 2016 Judge: BURLEY J Date of judgment: 21 March 2017 Catchwords: PRACTICE AND PROCEDURE – application for preliminary discovery – whether prospective applicant held reasonable belief of its right to obtain relief for patent infringement – whether additional requirements of r 7.23(1) of the Federal Court Rules 2011 (Cth) were satisfied – whether discretion under r 7.23(2) should be exercised – application dismissed
EVIDENCE – whether evidence admissible pursuant to s 76 of the Evidence Act 1995 (Cth) – whether rules of evidence should be waived pursuant to s 190
Legislation: Evidence Act 1995 (Cth) ss 76, 190
Federal Court of Australia Act 1976 (Cth) s 23
Federal Court Rules 2011 (Cth) rr 7.21, 7.23
Cases cited: C7 Pty Ltd v Foxtel Management Pty Ltd [2001] FCA 1864
Dallas Buyers Club LLC v iiNet Limited [2015] FCA 317; (2015) 112 IPR 1
Dasreef Pty Limited v Hawchar [2011] HCA 21; (2011) 243 CLR 588
EBOS Group Pty Ltd v Team Medical Supplies Pty Ltd (No 3) [2012] FCA 48; (2012) 199 FCR 533
John Holland Services Pty Ltd v Terranora Group Management Pty Ltd [2004] FCA 679
Jones v Dunkel [1959] HCA 8; (1959) 101 CLR 298
Makita (Australia) Pty Ltd v Sprowles [2001] NSWCS 305; (2001) 52 NSWLR 705
ObjectiVision Pty Ltd v Visionsearch Pty Ltd [2014] FCA 1087; (2014) 108 IPR 244
Optiver Australia Pty Ltd v Tibra Trading Pty Ltd [2007] FCA 1560; (2007) 163 FCR 554
Optiver Australia Pty Ltd v Tibra Trading Pty Ltd [2008] FCAFC 133; (2008) 169 FCR 435
Paxus Services Ltd v People Bank Pty Ltd [1990] FCA 723; (1990) 99 ALR 728
Reeve v Aqualast Pty Ltd [2012] FCA 679
Sabre Corporation Pty Ltd v Russ Kalvin’s Hair Care Company (1993) 46 FCR 428
Schmidt v Won [1998] 3 VR 435
St George Bank Ltd v Rabo Australia Ltd [2004] 211 ALR 147; (2004) 211 ALR 147
Valra Pty Ltd as Trustee for Abdul Rahim Valibhoy Family Trust v Mag Men Holdings Pty Ltd [2016] FCA 23; 110 ACSR 554
Date of hearing: 8 and 9 February 2017 Registry: New South Wales Division: General Division National Practice Area: Intellectual Property Sub-area: Patents and associated statutes Category: Catchwords Number of paragraphs: 177 Counsel for the Prospective Applicants: Mr R C Macaw QC with Mr C Dimitriadis SC
and Ms C CochraneSolicitor for the Prospective Applicants: DLA Piper Australia Counsel for the Prospective Respondent: Mr D K Catterns QC with Mr J S Cooke
and Mr D B LarishSolicitor for the Prospective Respondent: Ashurst Australia ORDERS
NSD 2149 of 2016 BETWEEN: PFIZER IRELAND PHARMACEUTICALS
First Prospective Applicant
WYETH LLC
Second Prospective Applicant
PFIZER AUSTRALIA PTY LTD ACN 008 422 348
Third Prospective Applicant
AND: SAMSUNG BIOEPIS AU PTY LTD ACN 611 890 094
Prospective Respondent
JUDGE:
BURLEY J
DATE OF…
Keep reading for free
Create a free CaseChat account to read Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2017] FCA 285
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
1. The application be dismissed.
2. The applicants pay the respondent’s costs.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
In the present application, SBA led evidence to challenge the basis upon which Pfizer contended that the requisite objectively held belief arose. To a substantial extent, that evidence raised factual conflicts which it was not possible for me to determine on an application of this kind, there being no cross-examination, among other difficulties. Those difficulties were compounded by the fact that Dr Ibarra gave evidence in reply that generally took issue with the evidence of SBA’s witnesses, and then challenged only specific propositions which were advanced. That had the effect of leaving unclear precisely which matters were the subject of disagreement. 4. CONSIDERATION4.1 FCR 7.23(1)(a) Pfizer relies on six contentions which it submits, when considered cumulatively, give rise to the conclusion that it has the requisite belief within FCR 7.23(1)(a). I consider each separately below, and then cumulatively when I express my conclusions.First contention: some admitted integers Pfizer observes that it is common ground between the expert witnesses that the BRENZYS manufacturing process for etanercept would satisfy the first three integers of claim 1 of each of the 34 and 36 patents and integer 1 of claim 1 of the 632 patent. In my view this point does not go very far. The expert evidence agreed that every process for the manufacture of etanercept would satisfy these integers. Those integers are present by reason of the fact that the protein of interest is etanercept. Accordingly, I regard this factor, taken alone, as neutral.Second contention: advantage and opportunity Pifzer contends that in the development of the process for making BRENZYS, SBK had incentives, due to the advantages set out in the patents of the claimed processes and the widely recognized importance of those advantages, and the opportunity, given that the patents had been published, to adopt the processes used in the patents. As to the incentive for a party such as SBK to utilise the patents, Pfizer points to the evidence of Dr Ibarra who summarises the effect of the patents. In relation to the 034 and 036 patents, Dr Ibarra says that the process provides an improved system for large-scale production of polypeptides in cell culture, which involves the provision of amino acids, glutamine, asparagine, inorganic ions and concentrations that support relatively high levels of viable cell density and cell production that result in lower accumulation of metabolic waste products. These advantages are, it is said, reflected in the integers of the claims, which provide ranges desirable for media formulations. Professor Mahler’s evidence refers to each of the patents. Dr Ibarra in her evidence in reply does not specifically take issue with the Professor’s evidence concerning the effect of the patents. He understands the 034 patent to be concerned with phase (b), upstream processing and in particular “Media Prep” feeding into the large-scale bioreactors. In particular, he understands it to be primarily directed to batch and fed-batch processes with minimal feeds, although perfusion processes are not necessarily excluded. He points out that although the 034 patent teaches that a culture medium with “one, several or all” of the characteristics set out in integers 5 – 9 of claim 1 of the 034 patent may be used to optimise cell growth he observes that the patent does not teach that a culture medium with one or more of those characteristics will necessarily optimize the conditions of cell grown, viability and/or protein production (including etanercept). Professor Mahler developed this point by reference to an example given in the 034 patent of the use of a medium containing glutamine and having a medium characteristic selected from the group selected from the ranges set out in integers 5 – 9 of claim 1. He notes that the example given demonstrated that the medium having none of the characteristics identified within the ranges in the claim demonstrated a growth rate of relevant cells that was similar to that which did fall within the ranges.